# Clear Cell Sarcomas: Genomic landscape and functional validation

Clear Cell Sarcoma (CCS) are rare sarcomas characterized by an aggressive phenotype with high metastatic potential, manifesting through frequent in-transit, lymphatic, and early distant metastases. The hallmark molecular aberration in CCS is a translocation event t(12;22)(q13;q12). The resulting oncogenic protein consists of EWSR1, a transcription factor fused to one of the CREB-family of transcription factors, in most cases ATF1, and less frequently CREB1 or CREM. Presently, surgical resection represents the only effective treatment option for CCS, leaving clinical (basket) trials as the standard of care for patients with metastatic disease. The identification of therapeutic vulnerabilities necessitates comprehensive bioinformatics and their validation requires informative disease models.

Dawid Krzeciesa

University Hospital Essen
West German Cancer Center
Translational Sarcoma Research Group (AG Bauer)
Hufelandstraße 55
45147 Essen

dawid.krzeciesa@uk-essen.de

2024 Dr. rer. medic. (Promotion at University Duisburg-Essen)
Thesis: “Genomic Landscape of Clear Cell Sarcoma” at University Hospital Essen,West German Cancer Center in Translational Sarcoma Research Group (AG Bauer)

2020 Master of Science (Water Science at University Duisburg-Essen)
Thesis: “Identification and validation of therapeutic targets in a novel cell line of Clear Cell Sarcoma” at University Hospital Essen,West German Cancer Center in Translational Sarcoma Research Group (AG Bauer)

2016 Bachelor of Science (Water Science at University Duisburg-Essen)
Thesis: “Analyse der Häufigkeit von BRAF Mutationen bei Klarzellsarkomen” at University Hospital Essen,West German Cancer Center in Translational Sarcoma Research Group (AG Bauer)

**Publications:**

*KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape*.

Mühlenberg T, Falkenhorst J, Schulz T, Fletcher BS, Teuber A, **Krzeciesa D**, Klooster I, Lundberg M, Wilson L, Lategahn J, von Mehren M, Grunewald S, Tüns AI, Wardelmann E, Sicklick JK, Brahmi M, Serrano C, Schildhaus HU, Sievers S, Treckmann J, Heinrich MC, Raut CP, Ou WB, Marino-Enriquez A, George S, Rauh D, Fletcher JA, Bauer S.

J Clin Oncol. 2024 Apr 20;42(12):1439-1449. doi: 10.1200/JCO.23.01197. Epub 2024 Feb 26.

*Plasma Sequencing for Patients with GIST-Limitations and Opportunities in an Academic Setting.*

Falkenhorst J, Grunewald S, **Krzeciesa D**, Herold T, Ketzer J, Christoff M, Hamacher R, Kostbade K, Treckmann J, Köster J, Farzaliyev F, Fletcher BS, Dieckmann N, Kaths M, Mühlenberg T, Schildhaus HU, Bauer S.

Cancers (Basel). 2022 Nov 9;14(22):5496. doi: 10.3390/cancers14225496.

*Linking reaction rate constants and isotope fractionation of ozonation reactions using phenols as probes.*

Terhalle J, Nikutta SE, **Krzeciesa DL**, Lutze HV, Jochmann MA, Schmidt TC.

Water Res. 2022 Feb 15;210:117931. doi: 10.1016/j.watres.2021.117931. Epub 2021 Dec 3.